ticagrelor has been researched along with Angina-Pectoris* in 1 studies
1 other study(ies) available for ticagrelor and Angina-Pectoris
| Article | Year |
|---|---|
Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year-old man.
A drug interaction leading to higher exposure to cyclosporine.. Cyclosporine and ticagrelor.. A 49-year-old man with a stable renal graft, managed with cyclosporine with stable trough blood concentrations for several years, was treated with ticagrelor for unstable angina pectoris.. The timeline was consistent with the appearance of an interaction, the interaction was confirmed by an increase in trough concentration of cyclosporine, and there were no alternative causes that by themselves could have caused the increase in cyclosporine exposure.. Cessation of ticagrelor.. Inhibition of CYP3A4 and P-glycoprotein by ticagrelor.. Clinicians should be aware of this potential interaction as ticagrelor is frequently prescribed in individuals using cyclosporine. Close monitoring of cyclosporine serum concentrations is warranted to avoid overdosing of cyclosporine. A pharmacokinetic study is needed to further examine the probable interaction between cyclosporine and ticagrelor. Topics: Adenosine; Angina Pectoris; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Monitoring; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Polypharmacy; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2018 |